BioStrand

Foundation date

06/02/2019

Sector

#Biotechnology / R&D Services

Subsector

BioStrand is the first company since the 1980s to come up with a completely new, out-of-the-box solution for genetic data analysis. Where next generation sequencing revolutionised sequence data generation in the last decade, BioStrand now revolutionises sequence data analysis.

BioStrand offers a revolutionary methodology for identifying similarities and variations in genetic data and detecting structural anchor points that will drive innovation.

The BioStrand methodology enables unprecedented accuracy and speed of operation in detecting similarities and variations in DNA, RNA and proteins. By detecting HYFTSTM, structural 3D information is automatically integrated into the analyses,  revolutionising  pattern and profile detection that are critical in understanding diseases and biological processes.

Upcoming events

Latest news

  • ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder

    19 hours ago

  • Confo Therapeutics awarded EUR 1.7M VLAIO grant to expand application of ConfoBody® drug discovery and development technology in rare diseases

    Tuesday June 28th 2022

  • MRM Health starts clinical trial with next-generation optimized consortium therapeutic MH002 in Pouchitis

    Tuesday June 28th 2022

Jobs by BioStrand